vTv Therapeutics Inc. – NASDAQ:VTVT
vTv Therapeutics stock price today
vTv Therapeutics stock price monthly change
vTv Therapeutics stock price quarterly change
vTv Therapeutics stock price yearly change
vTv Therapeutics key metrics
Market Cap | 38.29M |
Enterprise value | 23.69M |
P/E | -2.98 |
EV/Sales | 11.79 |
EV/EBITDA | -1256.48 |
Price/Sales | 17.47 |
Price/Book | -3.26 |
PEG ratio | 0.06 |
EPS | -8.87 |
Revenue | N/A |
EBITDA | -24.12M |
Income | -20.61M |
Revenue Q/Q | N/A |
Revenue Y/Y | 5455.55% |
Profit margin | -0.95% |
Oper. margin | -605.77% |
Gross margin | 0% |
EBIT margin | -605.77% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freevTv Therapeutics stock price history
vTv Therapeutics stock forecast
vTv Therapeutics financial statements
| Jun 2023 | 9K | -5.61M | -62433.33% |
|---|---|---|---|
| Sep 2023 | 0 | -6.65M | |
| Dec 2023 | -9K | -3.47M | 38644.44% |
| Mar 2024 | 1M | -4.86M | -486.5% |
| 2025 | 0 | -31.69M |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 22426000 | 28.83M | 128.56% |
|---|---|---|---|
| Sep 2023 | 14924000 | 29.43M | 197.23% |
| Dec 2023 | 11018000 | 29.56M | 268.35% |
| Mar 2024 | 54183000 | 28.19M | 52.04% |
| Jun 2023 | -6.16M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -4.83M | 0 | 473K |
| Dec 2023 | -2.91M | 4.40M | -282K |
| Mar 2024 | -7.33M | 0 | 50.14M |
vTv Therapeutics alternative data
| Aug 2023 | 13 |
|---|---|
| Sep 2023 | 13 |
| Oct 2023 | 13 |
| Nov 2023 | 13 |
| Dec 2023 | 13 |
| Jan 2024 | 13 |
| Feb 2024 | 13 |
| Mar 2024 | 16 |
| Apr 2024 | 16 |
| May 2024 | 16 |
| Jun 2024 | 16 |
| Jul 2024 | 16 |
vTv Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 5000 | 0 |
| Insider | Compensation |
|---|---|
Ms. Robin E. Abrams (1964) Executive Chairwoman of the Board | $420,000 |
-
What's the price of vTv Therapeutics stock today?
One share of vTv Therapeutics stock can currently be purchased for approximately $14.9.
-
When is vTv Therapeutics's next earnings date?
Unfortunately, vTv Therapeutics's (VTVT) next earnings date is currently unknown.
-
Does vTv Therapeutics pay dividends?
No, vTv Therapeutics does not pay dividends.
-
How much money does vTv Therapeutics make?
vTv Therapeutics has a market capitalization of 38.29M.
-
What is vTv Therapeutics's stock symbol?
vTv Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "VTVT".
-
What is vTv Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of vTv Therapeutics?
Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are vTv Therapeutics's key executives?
vTv Therapeutics's management team includes the following people:
- Ms. Robin E. Abrams Executive Chairwoman of the Board(age: 61, pay: $420,000)
-
How many employees does vTv Therapeutics have?
As Jul 2024, vTv Therapeutics employs 16 workers.
-
When vTv Therapeutics went public?
vTv Therapeutics Inc. is publicly traded company for more then 10 years since IPO on 30 Jul 2015.
-
What is vTv Therapeutics's official website?
The official website for vTv Therapeutics is vtvtherapeutics.com.
-
Where are vTv Therapeutics's headquarters?
vTv Therapeutics is headquartered at 3980 Premier Drive, High Point, NC.
-
How can i contact vTv Therapeutics?
vTv Therapeutics's mailing address is 3980 Premier Drive, High Point, NC and company can be reached via phone at +33 68410300.
vTv Therapeutics company profile:
vTv Therapeutics Inc.
vtvtherapeutics.comNASDAQ
16
Biotechnology
Healthcare
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
High Point, NC 27265
CIK: 0001641489
ISIN: US9183852048
CUSIP: 918385105
